- 2 سال پیش
- 204
- 46:51
PCSK9 inhibitors place in patients with cardiometabolic diseases
Daily cardiology
0
توضیحات
PCSK9 inhibitors from two perspectives of Endocrinologist & Cardiologist
Avatar
کاربر شنوتواولین نفر کامنت بزار
- 188
- 2 سال پیش
A brief talk on DM medication challenges in patients with CVD...
A brief talk on DM medication challenges in patien...
58:29
- 188
- 2 سال پیش
58:29
- 165
- 2 سال پیش
DOACs important interactions in clinical practice...
DOACs important interactions in clinical practice
06:38
- 165
- 2 سال پیش
06:38
- 171
- 2 سال پیش
OAC Management in Patients with CKD...
OAC Management in Patients with CKD
09:21
- 171
- 2 سال پیش
09:21
- 163
- 2 سال پیش
OAC Choice in High Thrombotic Risk Patients after ICH...
OAC Choice in High Thrombotic Risk Patients after ...
07:39
- 163
- 2 سال پیش
07:39
- 161
- 2 سال پیش
Any Concerns for OACs Use in Patients with Thrombocytopenia...
Any Concerns for OACs Use in Patients with Thrombo...
05:52
- 161
- 2 سال پیش
05:52
- 166
- 2 سال پیش
OAC of choice in patients with hepatic impairment, any difference between DOACs?...
OAC of choice in patients with hepatic impairment,...
05:38
- 166
- 2 سال پیش
05:38
- 175
- 2 سال پیش
Low dose Rivaroxaban in SIHD, COMPASS trial...
Low dose Rivaroxaban in SIHD, COMPASS trial
09:00
- 175
- 2 سال پیش
09:00
- 177
- 2 سال پیش
OAC choice in patients with obesity or low body weights, any role for DOACs?...
OAC choice in patients with obesity or low body we...
09:33
- 177
- 2 سال پیش
09:33
- 183
- 2 سال پیش
OAC of choice in patients with artificial heart valves...
OAC of choice in patients with artificial heart va...
11:30
- 183
- 2 سال پیش
11:30
تمامی حقوق این وبسایت متعلق به شنوتو است